Biogen (BIIB) PT Raised to $458 at Truist Securities
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $214.35 -3.25%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Truist Securities analyst Robyn Karnauskas raised the price target on Biogen (NASDAQ: BIIB) to $458.00 (from $443.00) while maintaining a Buy rating.
You May Also Be Interested In
- Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
- Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
- LB Pharmaceuticals Inc (LBRX) PT Raised to $69 at Clear Street
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
